Close Menu

A new Massachusetts-based startup company called Noblegen is trying to make a simpler version of nanopore genome sequencing technology, with the hope of making it cheap and fast enough for widespread use in clinical labs, reports Technology Review's Katherine Bourzac. The company's CEO Frank Feist says Noblegen's goal is to sequence at a rate of 50 base pairs per second, and that the technology could be scaled up to sequence about 30 genomes in 15 minutes, Bourzac adds.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Russia says its candidate SARS-CoV-2 vaccine has a very high efficacy rate in an initial analysis of clinical trial data, according to the Financial Times.

Wired reports on a microbial analysis of sketches drawn by Leonardo DaVinci.

A new survey explores coronavirus vaccine hesitancy among Black and Latino individuals, the Washington Post reports.

In Nucleic Acids Research this week: the Aging Atlas database, a database of human metagenome-related metadata, and more.